12V Stock Chart & Stats
€37.17
€0.18(0.36%)
At close: 4:00 PM EDT
€37.17
€0.18(0.36%)
Day’s Range― - ―
52-Week Range€25.98 - €52.72
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€3.08B
Enterprise Value€4.37B
Total Cash (Recent Filing)€485.23M
Total Debt (Recent Filing)€40.11M
Price to Earnings (P/E)29.9
Beta0.56
Next Earnings
Nov 04, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.44
Shares Outstanding80,390,730
10 Day Avg. Volume6
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€52.16Price Target Upside40.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.7
Revenue Forecast (FY)€528.35M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And ProfitabilityVeracyte has combined continued revenue expansion with a substantial profitability inflection. Rising sales and stronger net margins indicate improving operating leverage and commercial scale, while the consistently high gross margin supports the potential for durable earnings generation as genomic test adoption grows.
Cash GenerationRecent cash conversion is a meaningful fundamental strength because operating performance is translating into internally generated funds. Strong operating and free cash flow can support investment in test development, commercialization, and acquisitions while reducing reliance on external financing.
Low Financial LeverageThe conservatively financed balance sheet gives Veracyte substantial financial flexibility. Very low leverage limits interest and refinancing pressure, preserves capacity to fund strategic growth, and improves resilience if reimbursement conditions or diagnostic demand become less favorable over the next several quarters.
Bears Say
Decelerating Revenue GrowthAlthough revenue remains on an upward trajectory, slowing growth reduces the pace at which Veracyte can leverage its fixed commercial and laboratory infrastructure. Sustained deceleration could make future margin expansion harder and place greater importance on successful new-test launches and adoption.
Historical Earnings And Cash-Flow VolatilityThe recent profitability and cash-generation improvement has not yet eliminated evidence of business-cycle or execution volatility. Earlier losses and weak cash flow show that financial performance can deteriorate, so maintaining current margins and cash conversion remains important to the durability of the turnaround.
Acquisition Investment And Delayed CommercializationThe Convergent acquisition expands Veracyte’s urology platform but requires substantial upfront capital before the planned UroAmp launch. The long commercialization timeline creates execution and integration exposure, with the acquired technology’s eventual contribution dependent on reimbursement and clinical adoption.
Veracyte News
12V FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was €25.98 and its highest was €52.72 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is €3.08B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Nov 04, 2026 which is in 16 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Jul 30, 2026. The company reported €0.481 earnings per share for the quarter, beating the consensus estimate of €0.365 by €0.116.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.37.
How many shares outstanding does Veracyte have?
Veracyte has 80,390,730 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of €0.481 in its last earnings report, beating expectations of €0.365. Following the earnings report the stock price went down -1.099%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in DE:12V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€52.16 (40.34% Upside)
€52.16 (40.34% Upside)
Blogger Sentiment
Bullish
DE:12V Sentiment 89%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.41%
12-Months-Change
Fundamentals
Return on Equity
8.64%
Trailing 12-Months
Asset Growth
10.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Veracyte
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
12V Company Deck
12V Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: double-digit revenue and volume growth, margin expansion, robust adjusted EBITDA (30.8%), strong cash generation, and multiple near-term product catalysts (Prosigna LDT and TruMRD). The company emphasized a deep clinical evidence base, sustained Decipher momentum, operational wins on Afirma (V2 workflow), and continued investment in R&D and commercialization. Key risks discussed were binary clinical readouts (OPTIMA/ENZIMET), exclusion of new-product revenue from guidance, PPC variability, seasonal sample quality impacts, and the need for guideline/reimbursement progress—factors that inject execution and timing uncertainty but do not currently outweigh the suite of positive financial and commercial indicators.View all DE:12V earnings summaries12V Stock 12 Month Forecast
Average Price Target
€52.16
▲(40.34% Upside)